Literature DB >> 21145798

Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS.

Christophe Bureau1, Sophie Métivier, Mario D'Amico, Jean Marie Péron, Philippe Otal, Juan Carlos Garcia Pagan, Valérie Chabbert, Carine Chagneau-Derrode, Bogdan Procopet, Hervé Rousseau, Jaume Bosch, Jean Pierre Vinel.   

Abstract

BACKGROUND & AIMS: Refractory ascites in patients with cirrhosis is associated with poor survival. TIPS is more effective than paracentesis for the prevention of recurrence of ascites but increases the risk of encephalopathy while survival remains unchanged. A more accurate selection of the patients might improve these results. The aim of the present study was to identify parameters of prognostic value for survival in patients with refractory ascites treated with TIPS.
METHODS: One hundred and five consecutive French patients with cirrhosis and refractory ascites treated with TIPS were used to assess parameters associated with 1-year survival. The model was then tested in two different cohorts: a local and prospective one including 40 patients from Toulouse, France, and an external one including 48 patients from Barcelona, Spain.
RESULTS: The actuarial rate of survival in the first 105 patients was 60% at 1 year. Using multivariate analysis, only lower bilirubin levels and higher platelet counts were independently associated with survival. The actuarial 1-year survival rate in patients with both a platelet count above 75×10(9)/L and a bilirubin level lower than 50 μmol/L [3mg/dl] was 73.1% as compared to 31.2%, in patients with a platelet count below 75×10(9)/L or a bilirubin level higher than 50 μmol/L. These results were confirmed in the two different validation cohorts.
CONCLUSIONS: The combination of a bilirubin level below 50 μmol/L and a platelet count above 75×10(9)/L is predictive of survival in patients with refractory ascites treated with TIPS. This simple score could be used at bedside to help choose the best therapeutic options.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21145798     DOI: 10.1016/j.jhep.2010.08.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  28 in total

1.  Atherosclerotic splenic artery aneurysm in a decompensated cirrhotic patient.

Authors:  Radu Badea; Vasile Andreica; Cosmin Caraiani; Bogdan Procopet
Journal:  J Med Ultrason (2001)       Date:  2013-02-22       Impact factor: 1.314

2.  Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS).

Authors:  Sergio Maimone; Francesca Saffioti; Roberto Filomia; Angela Alibrandi; Grazia Isgrò; Vincenza Calvaruso; Elias Xirouchakis; Gian Piero Guerrini; Andrew K Burroughs; Emmanuel Tsochatzis; David Patch
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

3.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 4.  Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites.

Authors:  Guido Stirnimann; Vanessa Banz; Federico Storni; Andrea De Gottardi
Journal:  Therap Adv Gastroenterol       Date:  2017-01-05       Impact factor: 4.409

5.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

6.  Elective Transjugular Intrahepatic Portosystemic Shunt Using Viatorr Stent-Grafts: A Single-Center Experience from China.

Authors:  Yu-Hua Li; Yue-Meng Wan; Hua-Mei Wu; Song-Quan Huang
Journal:  J Belg Soc Radiol       Date:  2022-06-29       Impact factor: 1.912

Review 7.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

Review 8.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Outcomes of transjugular intrahepatic portosystemic shunts for ascites.

Authors:  Zachary L Bercu; Aaron M Fischman
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 10.  Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.

Authors:  Adelina Horhat; Christophe Bureau; Dominique Thabut; Marika Rudler
Journal:  United European Gastroenterol J       Date:  2021-02-23       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.